Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NW08

UPID:
RPC2_HUMAN

ALTERNATIVE NAMES:
C128; DNA-directed RNA polymerase III 127.6 kDa polypeptide; DNA-directed RNA polymerase III subunit B

ALTERNATIVE UPACC:
Q9NW08; A8K6H0; B3KV73; F5H1E6; Q9NW59

BACKGROUND:
The DNA-directed RNA polymerase III subunit RPC2, alternatively named DNA-directed RNA polymerase III 127.6 kDa polypeptide, is integral to synthesizing small RNAs, including 5S rRNA and tRNAs. It is a core component of RNA polymerase III's catalytic activity. Additionally, RPC2 has a unique role in the innate immune system, sensing and responding to intracellular bacterial and DNA virus infections by recognizing non-self dsDNA.

THERAPEUTIC SIGNIFICANCE:
The association of DNA-directed RNA polymerase III subunit RPC2 with diseases such as Leukodystrophy, hypomyelinating, 8, and Charcot-Marie-Tooth disease, demyelinating, 1I, underscores its therapeutic significance. Exploring the functions and mechanisms of RPC2 could lead to innovative treatments for these conditions, emphasizing the importance of targeted research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.